The hire of H&K befits Amgen's powerful status in the biotech market and highlights its concerns over new rules for biosimilars – copies of biopharma medicines that can be made after the patent on original products has expired.
It has been speculated by some industry watchers that the European Medicines Agency will grant approval for the first wave of biosimilars this year.
Finalisation of guidelines is expected within the next six months.
Amgen continues to be an H&K client in the US and Portugal. The agency won the European project account following an agency review last year (PRWeek, 5 August 2005).
It has been speculated by some industry watchers that the European Medicines Agency will grant approval for the first wave of biosimilars this year.
Finalisation of guidelines is expected within the next six months.
Amgen continues to be an H&K client in the US and Portugal. The agency won the European project account following an agency review last year (PRWeek, 5 August 2005).
